argenx SE (EBR:ARGX)
858.20
-1.20 (-0.14%)
Nov 19, 2026, 5:35 PM CET
argenx SE Revenue
argenx SE had revenue of $1.75B USD in the quarter ending September 30, 2026, with 52.13% growth. This brings the company's total for the last twelve months to $5.93B, up 60.78% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth. That makes argenx SE the 2,375th largest company in the world by revenue and 13th in Belgium.
Revenue (ttm)
$5.93B
Revenue Growth
+60.78%
P/S Ratio
10.26
Revenue / Employee
$3.18M
Employees
1,863
Market Cap
53.67B EUR
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full argenx SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.71% |
| Dec 31, 2012 | 4.00M | 9.75K | 0.24% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 8.52B |
| European Medical Solutions | 51.36M |
| Hyloris Pharmaceuticals | 9.83M |
| Onward Medical | 8.42M |
| Oxurion NV | 1.15M |
| Financière de Tubize | 13.26K |
| Celyad Oncology | 7.00K |
| BioSenic | -2.59M |
argenx SE News
- 2 days ago - argenx SE Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - Argenx price target raised to $1,350 from $1,215 at Piper Sandler - TheFly
- 6 days ago - Argenx price target lowered to $1,130 from $1,190 at Morgan Stanley - TheFly
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX - PRNewsWire
- 8 days ago - Roth Capital biotech analysts hold analyst/industry conference call - TheFly
- 9 days ago - argenx SE Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 10 days ago - argenx SE Announces Agreement to Acquire Unnatural Products, Inc. for Up to Approximately $1.15 billion - Nasdaq
- 10 days ago - Argenx to acquire Unnatural Products for $1.15B - TheFly